Antithrombotic Therapy for Prevention and Treatment of Ischemic Stroke

被引：0
作者：
Gregory W. Albers
机构：
[1] Stanford University Medical Center; Director,
[2] Stanford Stroke Center,undefined
来源：
Journal of Thrombosis and Thrombolysis | 2001年 / 12卷
关键词：
stroke; ischemia; anticoagulation; tPA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Atherosclerosis involving the cervical vessels, intracranial vessels, or the aorta is the most common cause of ischemic stroke. Occlusive lesions of small penetrating brain arteries cause small “lacunar” strokes, which account for about 20% of ischemic strokes. Emboli from a variety of cardiac sources, particularly atrial fibrillation, account for about 25%. Efforts to prevent and treat ischemic stroke are complicated by the variety of etiologies underlying it and the selection of antithrombotic or thrombolytic therapy appropriate to the particular etiology.
引用
收藏
页码：19 / 22
页数：3
相关论文
共 22 条
[1]  
Albers GW(1995)Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1581-1587
[2]  
Bates VE(2000)Intravenous tissue–type plasminogen activator for treatment of acute stroke: the Standard Treatment with Activase to Reverse Stroke (STARS) study JAMA 283 1145-1150
[3]  
Clark WM(1995)Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Stroke Study (ECASS) JAMA 274 1017-1025
[4]  
Hacke W(1998)Randomized double–blind placebo controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Second European–Australian Acute Stroke Study Investigators Lancet 352 1245-1251
[5]  
Kaste M(1999)Recombinant tissue–type plasminogen activator (Alteplase) for ischemic stroke 3–5 hours after symptom onset JAMA 282 2019-2026
[6]  
Fieschi C(1999)A randomized trial of intra–arterial prourokinase for acute ischemic stroke of less than 6 hours duration due to middle cerebral artery occlusion JAMA 282 2003-2011
[7]  
Hacke W(1997)The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke Lancet 349 1569-1581
[8]  
Kaste M(1998)Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial JAMA 279 1265-1272
[9]  
Fieschi C(2001)Antithrombotic and thrombolytic therapy for ischemic stroke Chest 119 300S-320S
[10]  
Clark WM(1997)CAST: a randomized placebo–controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke Lancet 349 1641-1649
123